Autoimmune Pancreatitis
19
1
1
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 19 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
9%
1 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (19)
Ambispective Validation of the Odesa Criteria 2026 (OC26): A Flexible Point-Based System for Diagnosis of Autoimmune Pancreatitis.
EchoTip AcuCore Post-Market Clinical Study
To Differentiate Focal Autoimmune Pancreatitis From Pancreatic Cancer by Endoscopic Ultrasound
Prospective Study on the Role of Eus-fnb in the Diagnosis of Autoimmune Pancreatitis
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions
Study on AI-assisted Multimodal Diagnosis System of Autoimmune Pancreatitis
CT Findings in Surgically Treated Focal Pancreatic Disease- A Retrospective Study
Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions
Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy
A Real-world Comparison of FNB and FNA in IHC-required Lesions.
Diagnostic Yield of FNA Needle and FNB Needle for Autoimmune Pancreatitis
Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis
Evaluation of EUS-guided FNA for Diagnosing Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)
CT Pancreas Perfusion
EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis